Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 1/20 | 0.44 |
| ▸ | ATP4B | P51164 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 10/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | SLC8A1 | P32418 | 4/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566450 | 1.00 | ATP4A (0.44) | ATP4AATP4BCYP3A4CYP2C9BRD4 | |
| SCHEMBL5567363 | 1.00 | ATP4A (0.44) | ATP4AATP4BCYP3A4CYP2C9BRD4 | |
| SCHEMBL5415404 | 0.91 | ATP4A (0.42) | ATP4AATP4BCYP3A4CYP2C9BRD4 | |
| SCHEMBL5411682 | 0.91 | ATP4A (0.44) | ATP4AATP4BCYP3A4CYP2C9CCNA2 | |
| SCHEMBL5417158 | 0.91 | ATP4A (0.42) | ATP4AATP4BCYP3A4CYP2C9BRD4 | |
| SCHEMBL5421021 | 0.91 | ATP4A (0.42) | ATP4AATP4BCYP3A4CYP2C9BRD4 | |
| SCHEMBL5417817 | 0.91 | ATP4A (0.46) | ATP4AATP4BCYP3A4CYP2C9RIPK1 | |
| SCHEMBL5989112 | 0.91 | ATP4A (0.46) | ATP4AATP4BCYP3A4CYP2C9RIPK1 | |
| SCHEMBL5414013 | 0.90 | ATP4A (0.41) | ATP4AATP4BCYP3A4CYP2C9BRD4 | |
| SCHEMBL5422357 | 0.90 | ATP4A (0.41) | ATP4AATP4BCYP3A4CYP2C9SLC8A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1696921-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058325-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | GIPR, SLC10A2, GRPR | ATP4A 96/4885ATP4B 259/4885CYP3A4 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.